Why 340B is central to the story

Craneware, the Edinburgh-headquartered provider of financial performance software to US hospitals and a FTSE AIM UK 50 constituent, has made no regulatory announcement since posting its Annual Report and AGM notice on 29 October 2026. (LSE:CRW) This article therefore returns to its FY26 results, published on 21 September, to examine a theme separate from the cyber incident: the US 340B drug pricing programme and the company's decision to reset Revenue expectations for the year to June 2027.

On the LSE delayed price for the 3 November session, the shares were 1,048p, down 0.38%.

What happened in FY26

Revenue was flat at US$206.0m (FY25: US$205.7m), while adjusted EBITDA rose 3% to US$67.1m and statutory profit before tax increased 7% to US$25.8m. (LSE:CRW) Annual Recurring Revenue was steady at about US$185m, and net revenue retention fell to 100% from 107%.

The company's explanation centres on 340B, a federal scheme that lets eligible US hospitals and clinics buy outpatient medicines at discounted prices. (LSE:CRW) According to the chair, customers could not realise opportunities identified by Craneware's 340B Shelter offering, so related transaction revenue did not grow, and signed licence revenue from its 340B rebate solution remained deferred pending regulatory clarification.

The shift towards rebates

Drug manufacturers have been introducing stricter data requirements, and policymakers have proposed testing rebate-based processes instead of upfront discounts. (LSE:CRW) Under a rebate model, hospitals would pay a higher initial price and then submit validated transaction data to recover the benefit. The company argues this adds working capital, data and compliance burdens for providers, which its software is designed to address.

Craneware says the reinstated 340B rebate pilot is expected to begin on 1 January 2027 and has sharpened market focus. It has launched Trisus OneLink - Medication, the first of a planned family of products to help hospitals identify eligible transactions, submit claims, reconcile rebates and keep audit-ready records. Management also states that wholesale legislative reform before the 2028 US elections looks comparatively unlikely.

How the outlook was framed

For FY27, the board has set revenue expectations at roughly the level of ARR, about US$185m, which by our calculation is around 10% below FY26 revenue. It describes this as a prudent view, reflecting the unquantified financial effects of the cyber incident and a cautious assessment of new and expansion revenues. A cost-base review is under way, with the aim of maintaining the group EBITDA Margin in the medium term.

The company says 340B tailwinds are expected to build in the second half of FY27 but are not included in its revenue expectations. On our reading, that leaves the pilot as potential upside to the reset base rather than a requirement to meet it, although the company stresses that timing depends on final rules, manufacturer participation and customer adoption.

Balance sheet and dividend

Cash was US$54.8m at 30 June 2026 and bank Debt US$43.5m, after drawing on the revolving Facility to help fund a US$25m share buyback. The board proposed a total Dividend of 32p, unchanged, comprising a 17p final. Subject to AGM approval, the final will be paid on 22 December 2026 to holders on the register on 4 December, with an ex-dividend date of 3 December. On the declared 32p total and the 3 November price, the trailing Yield is about 3.1%, our calculation.

Risks and dates

Risks include further regulatory delay or legal challenges to the pilot, slower customer adoption of new products, and the remaining costs and customer effects of the cyber incident, which the company says will take several financial periods to resolve. The AGM is on 27 November 2026 at 10am in Edinburgh, and interim results to 31 December will give the next detailed read on renewals and 340B demand.